CA 72.4

CA 72.4 is a specialized diagnostic laboratory test designed to measure the quantitative concentration of cancer antigen 72-4 (also known as tumor-associated glycoprotein 72 or TAG-72) in a blood sample. CA 72.4 functions as a tumor marker, a protein substance that can be elevated in the bloodstream in association with certain malignancies, most notably gastrointestinal cancers such as gastric (stomach) cancer, as well as ovarian and colorectal cancers. While it is not recommended for routine screening in asymptomatic individuals, it provides critical clinical utility when monitoring treatment response, assessing therapeutic efficacy, and tracking recurrence in diagnosed patients.

Measurement of serum CA 72.4 levels provides direct clinical insight into tumor burden, disease activity, and oncological status. Because elevated levels can also occasionally occur due to non-cancerous conditions such as benign gastrointestinal disorders, liver disease, or inflammation, specialized blood testing helps clinicians evaluate clinical progress when interpreted alongside imaging studies and physical examinations. Quantitative testing supplies precise data regarding circulating tumor marker concentrations.

The test requires a simple venous blood sample collected by a qualified phlebotomist using standard collection containers, followed by precise quantitative analysis using advanced laboratory immunoassay techniques. Results must always be interpreted in conjunction with the patient's clinical history, oncological evaluations, and symptoms.

Benefits of CA 72.4 Testing

• Provides a direct quantitative measure of CA 72.4 tumor marker protein circulating in the bloodstream.
• Helps monitor treatment response and detect recurrence in patients diagnosed with gastric or gastrointestinal cancers.
• Assists clinicians in tracking therapeutic efficacy during oncological management.
• Aids in assessing post-treatment remission alongside imaging and clinical examinations.
• Supports tracking of oncological health alongside specialized cancer care panels.
• Complements endoscopy, imaging studies, and physical examinations for comprehensive evaluations.
• Utilizes precise laboratory measurement techniques for reliable results.
• Assists specialists in determining appropriate cancer management strategies.
• Provides dependable turnaround times to support specialized clinical care.
• Utilizes a standard venous blood collection procedure.

Clinical Indications and Applications

Gastric Cancer Monitoring: The primary clinical indication is monitoring patients undergoing treatment for gastric (stomach) cancer or ovarian cancer to assess therapeutic response and track remission or recurrence.

Oncological Follow-up: The test is utilized during follow-up evaluations of previously treated patients to detect potential disease progression early.

Why Doctors Recommend This Test

Oncologists and physicians recommend this blood test when managing gastric or gastrointestinal cancer treatment, evaluating therapeutic progress, or monitoring patients for recurrence. It delivers essential quantitative data required to guide safe clinical intervention.

Preparation Before the Test

No special fasting is strictly required for a CA 72.4 test unless combined with other specialized metabolic panels. Patients should follow any specific instructions provided by their doctor or the laboratory. Inform the healthcare team about all current medications, recent therapies, and relevant medical history.

Wearing comfortable clothing with sleeves that can be easily rolled up will facilitate a smooth and efficient blood collection process.

What Happens During the Procedure?

The collection procedure involves a standard venous blood draw (venipuncture) performed by a skilled phlebotomist. A tourniquet is securely wrapped around the upper arm to enhance blood flow into the veins. The skin over the selected puncture site, typically inside the elbow or the back of the hand, is cleaned using an antiseptic wipe.

A sterile needle is gently inserted into the vein, and blood is collected into an evacuated collection tube or syringe. Patients may feel a brief, mild pinch or stinging sensation as the needle enters the skin. Once an adequate sample has been obtained, the needle is withdrawn, and gentle pressure is applied to the site using a clean cotton ball or gauze pad, secured with a small adhesive bandage.

The entire collection process takes only a few minutes. The labeled sample is then promptly transported to the laboratory for specialized immunoassay analysis.

Normal Reporting Time

The report for the CA 72.4 test is generally available within 24 to 48 hours due to specialized laboratory processing times. Results must be reviewed promptly with the referring physician or oncologist.

Who Should Consider This Test?

• Patients diagnosed with gastric, ovarian, or gastrointestinal cancers undergoing therapy.
• Individuals monitored for cancer recurrence following successful primary oncological treatment.
• Patients evaluated by oncologists for suspected gastrointestinal or ovarian malignancies.
• Individuals requiring specialized oncological marker assessments as directed by a specialist.

Understanding Test Results

Test results provide the quantitative concentration of CA 72.4, typically measured in units per milliliter (U/mL), evaluated against established laboratory reference intervals.

Normal Findings: Levels falling within established reference limits indicate no significant elevation of CA 72.4.

Elevated Findings: High levels can suggest gastric, ovarian, or colorectal malignancy recurrence, though benign conditions affecting the gastrointestinal tract or liver can also occasionally cause mild elevations.

Clinical Limitations

CA 72.4 is not recommended for routine cancer screening in healthy individuals because early-stage cancers may not cause marker elevations. Results must always be interpreted alongside imaging and clinical examinations.

Important Safety Information

Severe abdominal pain, persistent vomiting, or acute clinical symptoms require immediate medical attention. Patients must consult their healthcare provider to interpret tumor marker findings.